The difference between ibrutinib and acalabrutinib

Acalabrutinib is a drug used to treat chronic lymphocytic leukemia (CLL) and is associated with a lower risk of adverse events (such as atrial fibrillation) than ibrutinib. A 2021 Phase III study in the Journal of Clinical Oncology found that although the two drugs had similar efficacy, acalabrutinib was better tolerated and had fewer side effects. In clinical studies:1. Compared with ibrutinib, acalabrutinib was associated with a lower overall incidence of high blood pressure, diarrhea, joint pain, atrial fibrillation, back pain, urinary tract infections, muscle cramps, bruising, and indigestion. 2.Acalabrutinib was associated with an overall higher incidence of headache, cough, and fatigue compared with ibrutinib. 3.The incidence of 3 grade or higher infections was similar for both drugs: 30% of patients with ibrutinib developed these infections, compared with 30.8% of patients with acalabrutinib. 4.The most common serious side effects of acalabrutinib and ibrutinib are anemia, pneumonia and atrial fibrillation.

The researchers found thatacalabrutinibis a more selective inhibitor of Bruton's tyrosine kinase(BTK). Acalabrutinib and ibrutinib work by irreversibly binding to and destroying cancerous B lymphocytes. The increased selectivity of acalabrutinibmeans that the risk of off-target cells or non-cancerous cells is much lower than ibrutinib, resulting in a lower risk of adverse effects. There are generic drugs in Bangladesh, Laos and India. Different manufacturers have different specifications and prices. The price per box is about 1000 to 2000. Patients can choose the drug version according to their own economic situation. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to help you learn more about high-quality overseas drugs.